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Summary.-Comparisons between oestrogen-receptor (RE)-positive or negative
patients were made on a continuous series of 735 patients with primary breast
tumours seen at the major treatment centre in British Columbia between 1975 and
1978. RE positivity was commoner in older patients, and was not associated with
menopausal status independently of age. The concentration of receptor protein also
increased with increasing age, but was not affected by menopausal status. Neither
RE status nor quantity was associated with any of the epidemiological risk factors
studied, which included parity, age at first birth, weight, family history and exposure
to oestrogenic drugs and oral contraceptives. Patients with RE- tumours were more
likely to present with symptoms other than a breast lump, pain or nipple inversion,
and had less-differentiated tumours; they did not differ from RE+ patients in terms
of stage, size of tumour, or interval from first symptom. These findings are discussed
in terms of the biological origin and determinants of oestrogen receptors.
BREAST-CANCER PATIENTS with oestro-
gen-receptor-positive (RE+) tumours differ
from those with RE- tumours in their
response to hormonal therapy (McGuire,
1978), survival from diagnosis (Bishop et
al., 1979), time to first recurrence (Cooke
et al., 1979; Knight et al., 1977) and prob-
ably in their response to chemotherapy
(Lippman et al., 1978; Kiang et al., 1978).
Oestrogen positivity has also been re-
ported to vary with menopausal status
(Allegra et al., 1979), age (Fisher et al.,
1980), ethnic origin (Nomura et al., 1977)
and features of tumour such as histo-
logical grade (Maynard et al., 1978), degree
of elastosis (Masters et al., 1978), patho-
logical type (Rosen et al., 1975; Kern,
1979) and cell-doubling time (McGuire,
1978). A report based on 45 patients sug-
gests that RE- tumours are more common
in women who have had an oophorectomy
and have used oestrogenic drugs (Wallace
et al., 1978). These many studies, each
examining only a few factors, led us to
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consider a general hypothesis of system-
atic differences between the characteristics
of either the tumour or the patient in
association with RE status or quantity. If
RE status reflects distinct differences,
either in the host or in the pathogenic
mechanisms of the tumour, there may be
differences in RE status in terms ofknown
risk factors for breast cancer, and in the
clinical and pathological features of the
tumour, particularly those which may
reflect tumour activity, such as the staging
at diagnosis and the interval between first
symptom and diagnosis.
Accordingly, from a large continuous
series ofpatients referred to a major treat-
ment institution, we abstracted data on
RE status, and recognized breast-cancer
risk factors, and major clinical and patho-
logical characteristics. In keeping with
epidemiological principles, but in contrast
to many previous studies, we have assessed
the associations between RE status and
each of these characteristics, taking intoJ. M. ELWOOD AND W. GODOLPHIN
account the confounding effects of other
factors, ofwhich the mostimportant is age.
METHODS
Sources of data.-From the patient indices
at the A. Maxwell Evans Clinic in Vancouver
and at the oestrogen receptor laboratory of
the Vancouver General Hospital, we identi-
fied all patients who were referred to the
clinic for initial treatment ofa primary breast
tumour between 1975 and 1978 and who had
an oestrogen-receptor (RE) assay performed:
a total of 735 patients. All RE assays were
performed in the same laboratory under the
supervision of W.G. An admission-interview
record of standardized design was completed
on all patients, and life-long follow-up insti-
tuted. The records of these patients were
abstracted and coded in a standardized
manner by two abstractors, and the data on
RE status supplied independently from the
laboratory.
Laboratory methods.-Whole tumours were
frozen, transported (Muschenheim et al.,
1978) and stored in liquid N2 or at - 80°C.
Tumour tissue (0-2-0-5 g) was pulverized in
a Mikro-Dismembrator (B. Braun Melsungen
AG, W. Germany) (Wagner & Jungblut,
1976) and the powder reconstituted with
2-5 ml of cold TED buffer (10 mM Tris-HCl,
195 mM EDTA, 0-5 mM dithiothreitol, pH 7.5)
and centrifuged at 39,000 g, 0°C, for 15 min.
The supernatant protein concentration was
estimated spectrophotometrically (1.55 A280-
0 74 A260=mg protein/ml) and diluted with
TED buffer to yield 2 mg/ml. Supernatant
(250 jul) was mixed with 250 il cold TED
buffer containing either 100, 150 or 200 fmol
17 fl-[2,3,6,7-3H] oestradiol (New England
Nuclear, Boston, Mass., sp. act. 100 Ci/mmol)
or200fmol3H-oestradiolplus500pmolnafoxi-
dine ("U-li, IOOA", Upjohn Co., Kalamazoo,
Mich.). Blanks ofeach ofthe above mixtures,
without protein, were also prepared. All tests
were performed in duplicate and incubated
at 0-40C for 16-18 h. Unbound hormone was
removed by 30min incubation with 0 5 ml of
a suspension of 0.5% charcoal, 0-05%
Dextran 70 in TED buffer at 4°C. Dextran-
charcoal was removed at 12,000 g for 4 min.
The supernatant (0.5 ml) was mixed with
10 ml scintillation cocktail (Scintiverse,
Fisher Scientific, Fairlawn, N.J.) and counted
(Model LS-9000, Beckmann Instrument,
Irvine, Calif.) at 44% efficiency with auto-
matic data reduction to d/min after quench
correction.
Corrections were made for blanks and non-
specific binding, and the resultant specific
binding was expressed in fmol/mg protein. A
Binding Index (BI) was calculated at the
ratio (expressed as percentage) of specific to
total binding in the aliquot incubated with
200 fmol of 3H-oestradiol. Protein determina-
tions were by the Lowrymethod standardized
with crystalline bovine serum albumin.
Albumin concentrations ofthe tumour super-
natants were measured by radial-immuno-
diffusion (Behring, Hoechst Pharmaceuticals,
Montreal, Que.) and used to correct cytosol
protein concentration (EORTC Breast Cancer
Cooperative Group, 1973). A piece of tumour
representative of that used for receptor
analysis was placed in buffered formalin and
processed for microscopic histology.
Analyses of a rat-uteri quality-control pool
over 1 year indicated that the precision ofthe
receptor assay was about 15% at a mean
level of100 fmol/mg protein with a within-run
precision (as measured by the difference
between duplicates) of7%.
Tumours were considered to be RE+ ifthey
had a BI >40% and specific binding >6
fmol/mg cytosol protein. Those tumours with
a BI <20% and specific binding <3 fmol/
mg cytosol protein were considered RE-;
this was the highest seen in non-target and
normal breast tissue. Values falling between
these limits were considered indeterminate.
These limits are about equivalent to those
used by other investigators (McGuire et al.,
1975; Allegra et al., 1978; DeSombre et al.,
1978).
Statistical methods-.The association be-
tween RE positivity, determined as above,
and menopausal status was assessed by the
Mantel-Haenszel test (Mantel & Haenszel,
1959) and that with age by Mantel's test for
trend (Mantel, 1963); these both yield a x2
statistic with 1 d.f. and allow adjustment for
a covariate by stratification. Quantitative
data on RE concentrations were analysed
using the non-parametric Savage statistic
(Savage, 1956). In regard to epidemiological,
clinical and pathological features, we com-
pared patients with unequivocal RE+
tumours to those with RE- tumours, omitting
the intermediate group, and again used the
Mantel-Haenszel test for binary characteris-
tics and the Mantel test for ordered poly-
chotomous characteristics, after stratification
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TABLE I.-Oestrogen receptor (RE) status by age at diagnosis and menopausal status
All patients Premenopausal
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20 57
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27 68
19 74
14 81
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69
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19
9
7
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1
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8
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1
3
1
1
5
2
20
19
13
14
7
3
2
2
58
85
65
73
82
78
82
76
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All ages 526 64 145 72 133 24 56 62 390 39 88 75
Menopausal status was unknown for 5 patients under age 60; for 39 patients 60 and over no information
was given, but it is assumed these were postmenopausal.
Tests of trend in proportion RE+ with age: premenopausal X2 = 13-0, d.f. = 1, P < 0-001; postmenopausal
x2=2-9, d.f.=1,P>0-1.
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FIG. 1.-Proportion of patients with an
RE+ tumour, by ageandmenopausal status.
0- premenopausal, - -O- - postmeno-
pausal.
into 5 age groups. To describe the nature of
the association, we present the age-adjusted
odds ratio for having a positive tumour for
each defined patient group compared to a
reference group; an odds ratio > 1 means a
higher probability of an RE+ tumour.
RESULTS
Age and menopausal status
Of the 735 patients, 526 (72%) were
regarded as RE+, 145 (20%) as RE-, and
the remaining 64 (9%) were equivocal.
The proportion of positive tumours rose
with age from 43% in patients under 35
to 80% at ages 60-74, and then dropped
slightly in the oldest patients (Table I and
Fig. 1). The regular trend was broken by
an abrupt peak of78% RE+ at ages 45-49.
A test for trend in the proportion RE+
with age showed x2 = 22-5, P < 0 0001.
For premenopausal patients, the pro-
portion of RE+ tumours rose with in-
creasing age (Table I); this trend was
significant as assessed by the linear trend
statistic, x2 =13-0' P < 0 001. For post-
menopausal patients the proportion RE+
varied less regularly, with maxima at ages
65 to 79 and also at 45 to 49, and there
was no linear trend (X2=2-9, P>0 1). To
test whether menopausal status had an
influence on RE positivity when age is
controlled, we compared women within
the age range where there were reasonable
numbers of both pre and postmenopausal
women, which was 40-45 years. Within
this age range, 70% of premenopausal
(96/138) and 68% of postmenopausal
patients (76/112) had RE+ tumours, in
spite of the older mean age of the post-
menopausal group. After adjustment for
age by stratification into 5-year age groups,
the odds ratio for having a positive
tumour was 0-9 in postmenopausal as com-
pared to premenopausal patients x2 = 0 01,
P=0.9).
We then examined the quantitative
Age
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
7
8
23
35
61
77
73
94
77
36
19
9
7
nlI I *a I a I I A.
637J. M. ELWOOD AND W. GODOLPHIN
127
(107)
0
Cs
0
w
35-44 45-54 55-64 65-74
Age at diagnosis (years)
FIG. 2.-Median cytosol RE protein concen-
trations (fmol/mg cytosol protein) by
menopausal status and age at diagnosis, for
patients with RE assayed from the primary
breast neoplasm. Median concentrations
given above the bars: numbers of patients
in parentheses. * premenopausal, O
postmenopausal.
data on cytosol RE protein concentration
by age and menopausal status, for assays
based on the primary tumours only
(Fig. 2). For premenopausal women, the
concentrations rose with age from a
median value of 7 fmol/mg at ages under
34 to 26 fmol/mg at ages 45-54; the test
for a linear trend with age yielded x2 =
12X9, P=0 0003. For postmenopausal
women the median value rose from 13
fmol/mg at ages 35-44 to 127 fmol/mg at
ages 65-74, then dropping slightly to 113
at ages 75 and over, and the linear trend
test yielded X2 = 23 5, P < 0 0001. A com-
parison of the RE concentrations in pre-
and postmenopausal women, corrected
for age, showed no significant difference
(x2=0-59, P=0-4). A multiple-regression
analysis of age and menopausal status on
the logarithm of receptor concentration
(which is near-normally distributed)
showed consistent results: age was posi-
tively and significantly associated with
RE concentration (F=34 4, P<0-0001)
whilst menopausal status had no signifi-
cant association (F = 0 6, P = 0 4).
Of the 327 postmenopausal patients
under 65 years old, 75 had had a hyster-
ectomy without a bilateral oophorectomy.
These patients were functionally pre-
menopausal, and so an analysis was done
combining these patients with the pre-
menopausal group. This again showed no
association between RE status and men-
strual status when age is controlled. The
hysterectomized group of patients had
median RE concentrations of 7, 39 and
53 fmol/mg at ages 35-44, 45-54 and
55-64 years, respectively, thus showing
similar levels to those ofmenstruating and
of functionally menopausal women, and
a similar increase with age.
For patients within the age range 40-59
years, the RE+ rates were 62% in those
< 2 years postmenopausal, 68% in those
3-5 years, and 76% in those 6 or more
years postmenopausal; this trend in posi-
tivity persisted after adjustment for age
differences, but was not statistically sig-
nificant. Quantitative analysis showed no
association of RE concentration with
menopausal status, categorized as above,
after age adjustment (X2 trend= 0X04,
P=0.8) while again showing a significant
association with age controlled for meno-
pausal status (X2 trend= 10-3, P=0-0001).
Associations with breast-cancer risk factors
There was no significant association of
RE status with age at menopause, type of
menopause, or prior oophorectomy (Table
II). Age at menarche showed no significant
association when examined in categories
of < 12, 13, and 14+ years, but com-
parison of the 14+ category with all
others gave an odds ratio of IP75 (X2 = 4.4,
P< 0.05); such reclassification after pre-
liminary examination of the data compro-
mises the usual statistical tests and little
weight can be given to this result. There
wereno significant associationswith ethnic
origin, marital status, parity or age at
first birth although, again, comparison of
the small group of women whose first
birth was at or before age 19 with all other
gravid women yielded an odds ratio of
0 49 (X2 = 4 0, P < 0 05). There were no
significant associations with socio-econ-
omic status, weight, a family history of
breast cancer in first-degree relatives, or a
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TABLE II.-Associations of RE status with patient characteristics
RE+ RE- Age-
&1 s ,-1 adjusted
r Category No. % No. % odds ratio
All patients - 526 100
Age at menopause <44 68 19
(age >50 only) 45-49 99 28
50+ 193 54
Unknown 32
Type of menopause Natural 264 69
(ifmenopausal) Artificial 116 31
History ofoophorectomy No 402 96
(age 40-69 only) Yes 15 4
Age at menarche < 12 138 36
13 113 29
14+ 138 36
Unknown 137
Ethnic origin Caucasian 492 96
Other 18 4
Unknown 16
Marital status Married 344 67
Never married 38 7
Separated or divorced 41 8
Widowed 89 17
Unknown 14
Parity 0 125 24
1 72 14
2 128 25
3 99 19
4 47 9
5+ 50 10
Unknown 5
Age at first birth < 19 39 11
(ifparous) 20-24 132 39
25-29 101 30
30+ 69 20
Unknown 55
Socio-economic status 0 unskilled, unemployed 97 22
1 skilled manual 98 22
2 clerical 111 25
3 technical 66 15
4 professional 75 17
Unknown 79
Weight (kg) <49 30 6
50-59 149 32
60-69 162 35
70+ 124 27
Unknown 61
Family history-breast No 437 85
cancer in first-degree Yes 75 15
relatives Unknown 14
Use oforal contraceptives No 430 82
Yes 96 18
Use ofoestrogen drugs No 335 69
(age 40-79 only) Yes 153 31
R =reference category.
* P based on Mantel-Haenszel statistic.
t P based on Mantel test for trend.
145
15
22
43
8
59
26
99
4
36
40
26
43
134
8
3
101
11
14
17
2
33
19
34
29
14
15
1
21
33
30
15
12
23
25
33
25
26
13
14
40
39
30
22
118
23
4
101
44
82
35
100
19
28
54
69
31
96
4
35
39
26
1-0 (R)
0*94
1-00
1-0 (R)
1-12
1.0 (R)
0-92
1-0 (R)
0-92
1-61
94 1-0 (R)
6 0-61
71 1-0 (R)
8 0-96
10 0-98
12 1-02
23 1-0 (R)
13 1-15
24 1-03
20 0.99
10 0-92
10 0-87
21 1-0 (R)
33 2-33
30 1-62
15 1-99
17 1-0 (R)
19 0-89
25 0-86
19 0-70
20 0 75
11 0-64
33 1-0 (R)
32 1-21
24 1-05
84 1*0 (R)
16 0-73
70
30
70
30
1.0 (R)
0-83
1-0 (R)
1-08
p
0.94t
0-76*
0-88*
0-18t
0.37*
0.94*
0-86*
0-96*
0.75t
0-23t
0-25t
0.39t
0.30*
0.54*
0-84*
Factoi
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TABLE III.-Associations of RE status with clinical and pathologicalfeatures
Category
Painless lump
Pain +lump
Nipple inversion
Other
None
Unknown
0-1 month
2-5 months
6-11 months
12+ months
Unknown
TI <2cm
T2 2-1-4-9 cm
T3 5 cm+
T4 direct extension
Unknown
Pathological examination Yes
ofaxillary nodes No
RE+
No. %
357 69
52 10
30 6
72 14
6 1
9?
271
120
47
57
31
171
218
38
57
42
55
24
10
12
35
45
8
12
RE-
No. %
91 63
16 11
6 4
31 22
0
1
74
35
15
12
9
51
57
8
18
11
55
26
11
9
38
43
6
13
Age-
adjusted
odds ratio
1-0 (R)
0-89
0-68
0-56
00
1-0 (R)
1-00
0-88
1-25
1-0 (R)
1-18
1-34
1-06
435 83 121 83 1-0 (R)
91 17 24 17 0-88
NO none
Ni 1-3
NI 4+
N2, N3 fixed
Unknown
No
Yes
No
Yes
Unknown
Fairly well or well
differentiated
Poorly differentiated
or anaplastic
Unknown
165
130
104
35
1
38
30
24
8
1
48
36
22
14
40
30
18
12
1-0 (R)
1-09
1-55
0-82
484 92 133 92 1-0 (R)
42 8 12 8 0-84
315
186
25
180
124
222
63 90
37 50
5
59
41
34
71
40
64 1-0 (R)
36 1-06
32
68
1-0 (R)
0-36
P value
0-84*
0-11*
0.03*
0-60*
0-76t
0-72t
0-72*
0-72t
0-76*
0-84*
< 0-001*
R =reference category.
* P value based on Mantel-Haenszel statistic.
t P value based on Mantel test for trend.
history of use of either oral contraceptives
or oestrogen drugs. Examination by type
of drug, length of use, or dosage revealed
no differences. We also compared the
quantitative distribution of RE protein
concentrations between categories of each
of the factors described above, after con-
trolling for age; no significant differences
were found.
Clinical and pathologicalfeatures
The first symptom was classified as a
painless lump, pain or a painful lump,
nipple inversion, or "other" (Table III).
Symptoms other than a painless lump
tended to occur in association with an
RE- tumour, though this was significant
only for the "other" group, where the age-
corrected odds ratio was 0-56 (x2 = 4 4,
P < 0 05). There was no difference in the
interval from first symptom to diagnosis,
and no difference in the size ofthe tumour,
the number of positive axillary nodes, or
the presence of metastases. Pathological
grading was available on only 61% of
patients (further review is in progress);
poorly differentiated or anaplastic tumours
were significantly less likely to be RE+
(odds ratio 0-36, x2=17-6, P<0*0001).
The median RE protein concentration
Factor
First symptom
Interval from symptom
to diagnosis
Size of primary
(T stage)
No. ofinvolved axillary
nodes (N stage)
Distant metastases
Residual tumour
Pathological grade
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was 63 fmol/mg for poorly differentiated
tumours, compared to 79 fmol/mg for well
differentiated tumours, but this difference
was not significant (X2 = 0 2, P= 0 7).
DISCUSSION
The proportion of RE+ tumours in-
creased steadily from young ages to a peak
at ages 60-74, and then fell slightly. This
slight drop at older ages was less apparent
if an absolute cut-off value of RE protein
concentration was used, as the proportion
of tumours with an indeterminate RE
level rose at ages over 70. The smooth
increase in positivity with age was broken
only by a peak at ages 45-49. This rela-
tionship of RE status to age explained the
indirect association to menopausal status;
the high proportion of RE+ tumours in
postmenopausal women was due to their
older age, rather than to their menopausal
status, and in premenopausal and post-
menopausal patients of similar ages the
proportions with RE+ tumours were
similar. Most studies show that postmeno-
pausal women have higher RE+ rates than
do premenopausal women, but few have
assessed whether this is due to their post-
menopausal status or to their being older.
Allegra et al. (1979) did so on 328
patients and concluded that age had no
effect, within menopausal categories;
however, their data do show positive asso-
ciations of RE concentration with age for
pre- and postmenopausal patients separ-
ately, and their conclusion is based on
their failure to detect a statistically signifi-
cant effect of age, a finding which reflects
sample size as well as the true association.
They did not assess whether menopausal
status was related to RE content after
adjusting for age. Fisher et al. (1980)
studying 178 patients reported a strong
association of RE status with age, and a
weaker one with menstrual status; again
they did not attempt to separate the two
effects but their data suggest that the age
association is the stronger.
It is unlikely that the differences in RE+
at various ages are due simply to differ-
ences in the concentration of circulating
or tissue oestradiol and consequent satura-
tion of receptor. While conflicting results
are produced by analyses which combine
data from both premenopausal and post-
menopausal women (Sakai & Saez, 1976;
Theve et al., 1978; Meyer et al., 1979;
Nagai et al., 1979), data from postmeno-
pausal women analysed separately show a
positive correlation between plasma
oestrogen and tumour RE (Saez et al.,
1978). No correlation has been found
between tissue and plasma oestradiol con-
centrations (Nagai et al., 1979), or between
high oestrogen levels in tumour cytosol
fractions and low RE content (Fishman
et al., 1977). Although very high levels of
endogenous hormone potentially result in
low RE values (Meyer et al., 1979, 1978b;
Garola & McGuire, 1977; Horwitz &
McGuire, 1978) and higher levels of
progesterone in the premenopausal state
may limit oestrogen stimulation of RE
synthesis (Saez et al., 1978) it is unlikely
that false RE- assays will result (Sakai &
Saez, 1976; Fishman et al., 1977; Hahnel
& Twaddle, 1979). The RE content of
mammary tumours is inversely related to
the proliferative rate as measured by the
dT-labelling index (Meyer et al., 1977,
1978a; Silvestrini et al., 1979). Tumours
from young women have higher dT-
labelling indices and lower RE than
tumours from older women (Meyer et al.,
1978a) but differences in plasma oestrogen
levels do not account for this association
(Meyer et al., 1977). Meyer et al. (1979)
have suggested that one type of breast
cancer, characterized by rapid prolifera-
tion and low RE, occurs predominantly in
younger women and another, character-
ized by slow cell proliferation and high
RE, occurs predominantly in older women.
Our data show no association between
RE+ or the concentration of receptor pro-
tein and age at menarche, age at meno-
pause, ethnic origin, parity, age at first
birth, socio-economic status, weight and
family history. All these factors are risk
factors for breast cancer, and most
theories of their mode of action as risk
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factors involve hormonal mechanisms.
For some factors, such as ethnic origin,
our failure to find a significant difference
might only reflect small numbers, but for
most factors the numbers of patients in
each category examined are quite large,
and there is little suggestion of any asso-
ciation with RE status. So if the higher
risk of breast cancer in women with a late
first birth than in those with an early first
birth, for example, is due to a difference
in endogenous hormonal milieu, that
difference does not show itself in terms of
a different type of breast tumour as
assessed by RE status. We also found no
association of RE status with factors
reflecting major changes in hormonal ex-
posure, such as oophorectomy or the use
of oral contraceptive or oestrogenic drugs.
Wallace et al. (1978) reported, after study-
ing 45 patients, that a history of oophor-
ectomy and oestrogen use was more com-
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mon in those with RE- tumours; we have
failed to confirm this. The importance of
controlling for age is great in such studies;
if no age control is made, our data show
that RE-tumours are much more common
in users of oral contraceptives, but this is
entirely due to their younger age.
We found no difference between RE+
and RE- patients in terms of the interval
from symptom to diagnosis, or staging at
diagnosis. Thus the reported more aggres-
sive behaviour and higher tumour-doub-
ling rate (McGuire, 1978) of RE- tumours
is insufficient to produce a difference in the
extent of disease at diagnosis. However,
the RE- tumours were less differentiated.
Despite the similarities in terms of the
risk factors studied, the distribution ofage
at diagnosis is quite different for RE+ and
RE- tumours. The patient series we have
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FIG. 4.-Incidence rates by age per 100,000
women/year for breast cancer in British
Columbia, 1969-1973 ( ), and for
combined data from 5 Japanese cancer
registries, 1968-1972 (- --).
30 40 50 60 70 80
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FIG. 3.-Estimated incidence rates by age
per 100,000 women per year in British
Columbia for RE+ ( ) and for RE-
and intermediate tumours (- - -).
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reported is a consecutive series and,
although it is not truly representative of a
population based incidence series of the
disease due to factors affecting referral to
the institution, there is no reason why
these referral biases should work differ-
ently for RE+ and RE- patients. It is
therefore possible to apply the RE+ per-
centages by age from this series to inci-
dence data for the same population
(Ministry of Health of British Columbia,
1976) to construct age-incidence curves
for RE+ and RE- tumours independently
(Fig. 3). The incidence-age relationship
for each tumour type consists of two com-
ponents; at younger ages the incidence
rises about 25% per year of age, whereas
at older ages it rises only about 2% per
year. The difference between the curves
is produced by the incidence of RE+
tumours rising more rapidly than that of
RE- tumours, at ages below 45, and by
this steep rise continuing for 5 years
longer for RE+ tumours before changing
to the lower rate ofincrease characteristic
ofolder women. In Japanese, as compared
to North American populations, the inci-
dence of breast cancer is lower and this
difference is much greater in older women;
in fact the curve of total breast-cancer
incidence against age from combined
Japanese registry data (Fujimoto et at.,
1979) is similar to that of RE- tumours in
British Columbia (Fig. 4). The proportion
ofRE+ tumours in Japanese series appears
not to change with age or with meno-
pausal status (Nomura et al., 1977), thus
curves for RE+ and RE- tumours in
Japanese patients would be similar to the
combined incidence curve in Fig. 4. This
suggests that the factors producing the
difference in breast-cancer incidence be-
tween Japanese and western populations
may particularly affect the incidence of
RE+ tumours.
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